It's great that you're on Brukinsa (zanubrutinib) and that your care team is keeping a close eye on things. The "how long does it last" question is one many people on this treatment wonder about.
Brukinsa is a BTK inhibitor, which works by blocking signals that tell cancer cells to grow. For lymphoma types like yours, it's Show Full Answer
It's great that you're on Brukinsa (zanubrutinib) and that your care team is keeping a close eye on things. The "how long does it last" question is one many people on this treatment wonder about.
Brukinsa is a BTK inhibitor, which works by blocking signals that tell cancer cells to grow. For lymphoma types like yours, it's approved for use after at least one prior treatment.
Your care team's estimate of around a year is in line with what's generally seen in clinical data for moderately aggressive lymphoma — though individual responses can vary quite a bit based on factors like:
- How well the lymphoma responds initially
- Your overall health
- Whether the disease has any other genetic markers
- How closely you're monitored during treatment The absence of a TP53 mutation is actually considered a more favorable factor, which is encouraging news. Patients without TP53 mutations tend to respond better and for longer to treatments like Brukinsa.
It's worth having an open conversation with your oncologist about what signs they'll be watching for, and what the next steps might look like if the treatment response changes over time. Staying informed and proactive is one of the best things you can do right now.
June 22
Join
Your Privacy Choices
